Xinhua News Agency, London, April 27 (Reporter Zhang Jiawei) The University of East Anglia in the United Kingdom released a study on the 27th, saying that an experimental urine test developed by its researchers has the potential to improve the efficiency of prostate cancer detection and make doctors understand faster The extent of the disease and whether in-depth testing is required to reduce the risk of patients being overdiagnosed and overtreated.
Prostate cancer usually develops slowly, and the detection techniques currently used include blood tests, MRI scans, and prostate biopsy.
However, doctors have long lacked better detection methods to predict whether such tumors will become malignant, which affects treatment judgments.
The urinalysis technology developed by researchers at the school comprehensively evaluates the expression levels of a protein marker called EN2 and 10 genes related to prostate cancer risk.
The team used this non-invasive new detection method on the urine samples of 207 patients and compared the results of their previous prostate biopsies.
The results show that the new detection technology can successfully analyze which patient has prostate cancer, and can form relevant risk indicators for each patient, so as to tell the doctors which of them need further prostate biopsy to avoid The patient is overdiagnosed and overtreated.
Darn Brewer, a researcher at the University of East Anglia who led the study, said that invasive prostate biopsy will impose a greater burden on patients in economic and psychological aspects, and will also bring higher costs to the medical system.
The new urine test technology can help avoid this situation, and it can show the severity of the condition, so that doctors and patients can choose the most appropriate treatment.
The results of this research have been published in the latest issue of the British journal Cancer.